Company intelligence / Profile preview

Teneobio

Newark, California, United States

Ownership: Private
Employees: ~79
Development stage: Other

Overview

Teneobio advanced a pipeline of heavy chain-only multispecific and bispecific antibodies for oncology and immune disorders, with next-generation platforms for novel target engagement. Lead programs reached Phase 1/2 including anti-BCMA x CD3 (ABBV-383/TNB-383B, licensed to AbbVie), anti-PSMA x CD3 (TNB-585, discontinued by Amgen), and anti-CD19 x CD3 (AZD0486/TNB-486, now with AstraZeneca). Several assets were spun out or licensed prior to Amgen's acquisition in 2021[3][5][10].

Therapeutic areas: OncologyInfectious DiseasesImmunology
Modalities: AntibodyBispecific monoclonal antibodyMonoclonal antibodyAntibody-drug conjugate
Industry: Biotech

Partnerships

AbbVie (ABBV-383/TNB-383B, anti-BCMA; acquired TeneoOne)[5][10]AstraZeneca (AZD0486, anti-CD19 x CD3; acquired TeneoTwo)[5]Johnson & Johnson (anti-CD22 x CD3)[5]Ancora Biotech (spinout, inherited certain pipeline assets)[8]

Beyond the preview

Go deeper on Teneobio.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Teneobio.

Explore the full profile